The Pharmacy Benefit Manager Transparency Act of 2025 outlaws several PBM practices the bill characterizes as unfair or deceptive — most notably retaining differences between what PBMs charge payors and what they reimburse pharmacies, and retroactive reductions or “clawbacks” of pharmacy payments — while carving narrow exceptions tied to full pass‑through and robust disclosure. It also bans knowingly false reporting to federal agencies, protects covered individuals who report violations, and forbids predispute arbitration for whistleblower claims.
The bill layers a new compliance regime on PBMs: annual reporting of aggregate spreads, fees, clawbacks, formulary tier moves, and differential treatment of PBM‑owned pharmacies to the Federal Trade Commission (FTC) and HHS; a mandated GAO study of PBM market structure and practices; FTC enforcement authority including civil penalties; and preserved state enforcement. For operators in the prescription supply chain, the measure raises transparency requirements, enforcement exposure, and data‑management obligations that could shift incentives around rebates, formulary design, and vertical affiliation.
At a Glance
What It Does
The bill prohibits PBMs from retaining the spread between amounts charged to payors and amounts reimbursed to pharmacies, from arbitrary clawbacks, and from raising fees to offset federal reimbursement changes, unless they meet pass‑through and disclosure conditions. It requires annual reporting to the FTC and HHS on spreads, fees, clawbacks, formulary tier moves, and PBM‑owned pharmacy differentials, plus a GAO study and FTC reports to Congress.
Who It Affects
Pharmacy benefit managers (and their affiliates, subsidiaries, and agents), pharmacies (including PBM‑owned pharmacies and independent pharmacies), health plans and payors (public and private), drug manufacturers, and federal regulators including the FTC, HHS, and GAO. State attorneys general retain enforcement rights under the bill.
Why It Matters
By forcing detailed, recurring disclosure and by creating prohibitions backed by FTC civil penalties and private whistleblower remedies, the bill targets the economics of rebates, clawbacks, and formulary placement — practices that shape patient cost sharing and pharmacies’ cash flows. Compliance, data security, and definitional questions could meaningfully change PBM operations and bargaining leverage across the pharmaceutical supply chain.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates three complementary tracks: prohibitions on specific PBM conduct, a transparency and reporting regime, and strengthened enforcement and whistleblower remedies. First, Section 2 makes it unlawful for a PBM (including affiliates and agents) to (a) charge a plan more for a drug’s ingredient cost or dispensing fee than it reimburses the pharmacy and keep the difference; (b) arbitrarily claw back or reduce reimbursements except where the claim was fraudulent, inconsistent with contract terms, or services were not rendered; and (c) increase fees or lower pharmacy reimbursement to offset federal reimbursement changes.
Those prohibitions have narrowly drawn exceptions if the PBM returns 100% of price concessions to the payer and provides full disclosure of costs, fees, and aggregate manufacturer remuneration to contracting parties.
Second, the bill requires annual disclosures to both the FTC and HHS. PBMs must report aggregate spreads between payer charges and pharmacy reimbursements, amounts characterized as generic effective rate fees or direct/indirect remuneration charged to pharmacies, clawbacks rescinded during the year, explanations for formulary tier moves that increase patient cost or lower pharmacy reimbursement, and differential treatment where the PBM owns or is affiliated with a pharmacy.
The FTC must publish anonymized summaries to Congress and the GAO must report on market concentration, rebate flows, formulary incentives, prior‑authorization timeliness, step therapy drivers, and whether PBM prices to payors exceed amounts they pay pharmacies.Third, enforcement and remedies are robust: the FTC enforces the statute as an unfair or deceptive practice under the FTC Act, with powers to seek remedies and an added civil penalty of up to $1,000,000 per violating person (with each day of a continuing violation counted separately). State attorneys general may sue on behalf of residents, subject to notice to the FTC and other procedural rules.
The bill protects covered individuals who report suspected violations with anti‑retaliation provisions, waives enforceability of predispute arbitration clauses for these claims, and permits jury trials with remedies including reinstatement and double back pay. Privacy caveats require disclosures to avoid identifying patients or prescribers and to comply with HIPAA‑aligned privacy rules.
The Five Things You Need to Know
The bill makes it unlawful for a PBM to retain the difference between what it charges a health plan and what it pays a pharmacy for a drug’s ingredient cost or dispensing fee, unless it returns 100% of price concessions and fully discloses pricing and rebate information.
PBMs must begin annual reporting to the FTC and HHS within one year of enactment and thereafter each year, covering aggregate spreads, fees, clawbacks, formulary tier moves, and differential treatment of PBM‑owned or affiliated pharmacies.
The FTC enforces the statute as an unfair or deceptive practice, the law explicitly covers insurers and nonprofit organizations, and it authorizes an additional civil penalty of up to $1,000,000 per violating person, with each day of a continuing violation treated separately.
Whistleblowers (employees, contractors, agents) receive strong protections: a private right of action with jury trial, reinstatement, twice back pay, compensatory damages and attorneys’ fees, and a prohibition on enforcing predispute arbitration clauses for these claims.
The GAO must deliver a comprehensive one‑year study quantifying PBM market share among the 10 largest PBMs, rebate flows (what rebates are passed to patients, payors, and retained by PBMs), prior‑authorization timelines, step‑therapy drivers, and competitive impacts, with legislative recommendations.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Prohibited PBM conduct and limited exceptions
Section 2 delineates three core prohibitions: retaining the spread between amounts charged to payors and pharmacy reimbursements; arbitrary clawbacks or rescissions of payments; and shifting costs to pharmacies to offset federal reimbursement changes. The exceptions require two conditions together: the PBM passes 100% of price concessions to the health plan or payer and provides full disclosure of costs, fees, markups, discounts, and aggregate manufacturer remuneration to contracting payors, plans, and pharmacies. Practically, this transforms what had been contractual flexibility into compliance checkpoints: PBMs must document pass‑throughs and disclosures or face liability.
Ban on knowingly false reporting to federal agencies
Section 3 criminalizes—or at least civilly forbids—reporting information to federal departments or agencies that the reporter knew or reasonably should have known was false when the information was legally required and the falsehood would affect the agency’s statistical or market analysis. This provision targets misleading submissions that could obscure PBM market dynamics or rebate flows and creates separate exposure for misinformation supplied to government analysts.
Annual disclosure requirements to FTC and HHS
Section 4 requires PBMs (and affiliates/subsidiaries/agents) to submit annual, aggregate data within one year of enactment and every year thereafter: spreads between payor payments and pharmacy reimbursements, generic effective rate fees and other remuneration charged to pharmacies, amounts clawed back, reasons for formulary tier changes that increase consumer cost or lower pharmacy reimbursement, and comparative data for PBM‑owned pharmacies. The FTC may publish anonymized summaries to Congress but must protect trade secrets; HHS receives the same data. The bill also instructs the GAO and FTC to produce complementary reports evaluating formulary design incentives and market concentration.
Whistleblower protections and remedies
Section 5 broadly protects covered individuals (employees, contractors, agents) who report suspected violations to Congress, federal agencies, State attorneys general, or regulators. It prohibits retaliation, permits jury trials in federal court, and authorizes reinstatement, twice back pay, consequential and compensatory damages, and attorneys’ fees. The provision bars enforcement of predispute arbitration agreements and waivers of these rights, increasing the likelihood of public litigation when claims arise.
FTC enforcement, civil penalties, and state enforcement
Section 6 folds statutory violations into the FTC Act’s unfair or deceptive practices framework, giving the FTC investigatory and remedial authority and adding a separate civil penalty of up to $1,000,000 per violating person (with continuing daily violations). The section removes several jurisdictional shields — explicitly covering nonprofits and insurance business — and preserves state attorneys general rights to sue, subject to notice and intervention rules that allow the FTC to join or appeal state actions.
Limits on patient‑identifying information
Section 7 requires that any disclosures required under the Act not identify patients or prescribing providers. Combined with Section 4(d), PBMs must follow HIPAA‑aligned privacy, security, and breach‑notification rules when transmitting required data, which raises practical questions about deidentification standards and data aggregation to permit useful oversight while protecting PHI.
Interaction with state law and definitions
Section 8 preserves State laws and enforcement, stating the Act does not preempt state requirements. Section 9 supplies operational definitions (e.g., PBM, pharmacy benefit management services, prescription drug, health plan, covered individual), which are central to scope: the statute applies whenever a PBM provides services under a written agreement, including formulary management, claim processing, prior authorization, and network contracting.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Independent and community pharmacies — The ban on arbitrary clawbacks and the reporting on spreads could curb retroactive reimbursement reductions and give independent pharmacies evidence to negotiate or litigate unfair payment practices.
- Health plans and employers — Greater visibility into PBM spreads, fees, and rebate retention helps payors evaluate whether PBM arrangements deliver net savings and allows them to demand contractual pass‑through or different pricing models.
- Patients (especially those with cost‑sharing tied to formulary tiers) — Required disclosure of formulary tier moves and the GAO/FTC inquiries into whether PBMs favor high‑rebate drugs could increase pressure to align formularies with lower net patient costs.
- Federal regulators and Congress — The FTC, HHS, and GAO gain structured data and statutory authority to analyze PBM market dynamics and recommend or pursue policy remedies.
- Whistleblowers and compliance personnel — Strong anti‑retaliation rules and elimination of predispute arbitration for these claims create practicable avenues to surface misconduct without mandatory internal arbitration.
Who Bears the Cost
- Pharmacy Benefit Managers — PBMs face increased compliance and reporting costs, new litigation and penalty exposure (including daily continuing violations), and potential operational changes if pass‑through or disclosure requirements eliminate profitable spread capture.
- PBM‑owned or vertically affiliated health systems/pharmacies — Greater reporting of differential reimbursement and scrutiny may reduce the benefit of vertical integration or invite antitrust analysis.
- Federal agencies (FTC, HHS, GAO) — The FTC and HHS must process, secure, and analyze copious PBM data; GAO must conduct a broad study, creating resource and coordination burdens.
- Drug manufacturers — The requirement to disclose aggregate remuneration retained by PBMs can subject manufacturer‑PBM deals to greater scrutiny and administrative burdens, and could reduce the leverage of rebate‑driven contracting.
- Plans and plan sponsors that rely on existing PBM contracts — If PBMs respond by altering pricing models (e.g., shifting to higher list prices with fewer rebates), plans may see short‑term disruption and must reassess contract terms and pass‑through provisions.
Key Issues
The Core Tension
The central tension is between public interest in transparency and accountability of PBM conduct that affects drug prices and pharmacy viability, and the private interest in preserving confidential commercial negotiation, bargaining leverage, and patient privacy; measures that increase visibility can expose trade secrets, create new compliance costs, and prompt PBMs to rearrange compensation structures in ways that may or may not lower total consumer costs.
The bill forces a difficult balance between transparency and protecting legitimate commercial confidentiality. Requiring detailed annual disclosures and aggregate breakdowns of rebates, fees, and spreads will produce valuable oversight data but also raises the risk that competitively sensitive information could leak or be inferable despite anonymization.
The statutory protection for trade secrets and the FTC’s anonymized reporting requirement mitigate this, but practical deidentification standards and enforcement of nondisclosure will determine whether the data are both useful and secure.
Implementation will be operationally heavy. PBMs and regulators must agree on definitions, reporting formats, and aggregation levels; otherwise the datasets may be inconsistent or noncomparable across firms and years.
The bill’s exception — full 100% pass‑through plus full disclosure — is a blunt instrument that could encourage PBMs to redesign contracts (for example, moving away from per‑claim spreads toward administrative fees or list price increases) to preserve revenue while appearing compliant. That could shift costs to different actors (patients, manufacturers, or plans) in ways the statute does not directly address.
Finally, proving the statute’s key offenses (e.g., whether a clawback was “arbitrary, unfair, or deceptive”) will often hinge on contract terms, intent, and complex billing flows, leaving room for litigation over factual predicates and the scope of the affirmative defense.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.